文献速递胸部肿瘤头颈与中枢神经肿瘤

贝伐珠单抗减少S100A9阳性MDSC并与EGFR突变肺腺癌颅内控制相关

Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma.
PubMed 文献 · J Thorac Oncol · 2018-04-21

本研究纳入55例IV期EGFR突变肺腺癌患者,比较EGFR-TKI联合贝伐珠单抗(BEV/TKI组25例)与单用EGFR-TKI(TKI单药组30例)的疗效及免疫指标。BEV/TKI组PFS更长(23.0 vs 8.6个月,p=0.001),颅内控制率更高(80.0% vs 43.0%,p=0.03),且循环MDSC比例下降、Th1和CTL比例上升,提示BEV通过减少S100A9阳性MDSC恢复抗肿瘤免疫。

要点

  • BEV/TKI组PFS 23.0个月,显著长于TKI单药组8.6个月(p=0.001)。
  • BEV/TKI组颅内控制率80.0%,高于TKI单药组43.0%(p=0.03)。
  • BEV治疗后可降低循环MDSC比例并提升Th1和CTL比例。

核心结论

  • EGFR-TKI联合BEV延长PFS并保护脑转移,可能通过减少循环S100A9阳性MDSC恢复抗肿瘤免疫。
  • 数据支持BEV与免疫检查点抑制剂联合的理论基础。

研究设计与样本

  • 研究纳入55例IV期EGFR突变肺腺癌患者,BEV/TKI组25例,TKI单药组30例。
  • 采用流式细胞术分析MDSC、Th1/Th2和细胞毒性T淋巴细胞,并收集临床数据分析。

主要发现

  • BEV/TKI组PFS为23.0个月,TKI单药组为8.6个月(p=0.001)。
  • BEV/TKI组颅内控制率80.0%,TKI单药组43.0%(p=0.03)。
  • BEV/TKI组至颅内进展时间49.1个月,TKI单药组12.9个月(p=0.002)。
  • BEV/TKI组新发脑转移率38.0%,TKI单药组71.0%(p=0.03)。
  • BEV/TKI组治疗后循环MDSC比例从20.4%±6.5%降至12.8%±6.6%(p=0.02),Th1从22.9%±15.3%升至33.2%±15.6%(p<0.01),CTL从15.5%±7.2%升至21.2%±5.6%(p<0.01),TKI单药组无此变化。

关键数值与推荐

  • 治疗前MDSC比例与PFS相关,BEV/TKI治疗后该相关性减弱。
  • MDSC比例与至颅内进展时间缩短相关。

临床怎么用

  • 对于EGFR突变肺腺癌患者,可考虑EGFR-TKI联合BEV以延长PFS并改善颅内控制。
  • 循环MDSC比例可能作为预测BEV联合治疗获益的潜在生物标志物。
  • BEV联合免疫检查点抑制剂的策略值得进一步临床探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In vitro models have demonstrated immune-modulating effects of bevacizumab (BEV). Combinations of an EGFR tyrosine kinase inhibitor (TKI) with BEV improve progression-free survival (PFS) in patients with EGFR-mutated lung adenocarcinoma. How BEV confers this clinical effect and the underlying mechanisms of its effect are not clear. METHODS: A total of 55 patients with stage 4 EGFR-mutated lung adenocarcinoma were enrolled. Myeloid-derived suppressor cells (MDSCs), type 1 and type 2 helper T cells, and cytotoxic T lymphocytes were analyzed by flow cytometry. Clinical data were collected for analysis. RESULT: In all, 25 patients received EGFR TKI and BEV combination therapy (the BEV/TKI group) and 30 patients received EGFR TKI monotherapy (the TKI-only group). The BEV/TKI group had longer PFS (23.0 versus 8.6 months [p = 0.001]) and, in particular, better intracranial control rates (80.0% versus 43.0% [p = 0.03]), a longer time to intracranial progression (49.1 versus 12.9 months [p = 0.002]), and fewer new brain metastases (38.0% versus 71.0% [p = 0.03]) than the TKI-only group did. The BEV/TKI group had a lower percentage of circulating MDSCs (20.4% ± 6.5% before treatment versus 12.8% ± 6.6% after treatment, respectively [p = 0.02]), and higher percentages of type 1 helper T cells (22.9% ± 15.3% versus 33.2% ± 15.6% [p < 0.01]) and cytotoxic T lymphocytes (15.5% ± 7.2% versus 21.2% ± 5.6% [p < 0.01]) after treatment, changes that were not seen in the TKI-only group. Pretreatment percentage of MDSCs was correlated with PFS, with this correlation attenuated after BEV/TKI treatment. Percentage of MDSCs was also associated with shorter time to intracranial progression. CONCLUSION: Combining a EGFR TKI with BEV extended PFS and protected against brain metastasis. Those effects were probably due to the reduction of circulating S100A9-positive MDSCs by BEV, which leads to restoration of effective antitumor immunity. Our data also support the rationale for a BEV-immune checkpoint inhibitor combination.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Feng PH, Chen KY, Huang YC, et al. Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma. J Thorac Oncol. 2018. PMID: 29684573. doi:10.1016/j.jtho.2018.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。